Trivellato, M., Zustovich, F., Canton, R., Buratin, L., Pastorelli, D., Ceravolo, R., Binato, S., Salmaso, F., Zovato, S., Caliandro, A., Michielin, R. and Cartei, G. (2004) High incidence of EKG changes in patients treated with 5FU protracted infusion evidenced by a new 7-days-EKG-monitoring device (R-Test Evolution 3TM). Proceedings of European Society of Medical Oncology, Annals of Oncology, 15(Suppl 3), 407.

has been cited by the following article:

• TITLE: Cardio-Toxicity during chemotherapy: feasibility of new diagnostic approaches

  AUTHORS: Fable Zustovich, Mario Trivellato, Renato Ceravolo, Davide Pastorelli, Rosanna Canton, Lorena Buratin, Monica Mion, Martina Zaninotto, Martina Mattiazzi, Mario Plebani, Giuseppe Cartei

  KEYWORDS: Cardio-Toxicity Diagnostic

  JOURNAL NAME: Health, Vol.2 No.4, May 4, 2010

  ABSTRACT: Chemotherapy induced cardio-toxicity is a well known side effect of anticancer treatments, moreover the 70% of all tumors involve patients over 65 years-old, frequently with cardiac co- morbidity. We evaluated the feasibility of the application during chemotherapy administration of some of the most recent diagnostic techniques as 12-diagnostic leads telemetry, 7 days EKG monitoring device (R-Test Evolution 3R), blood level dosage of Brain Natriuretic Peptide (BNP) and Ischemia Modified Albumin (IMA). Some sub-clinical changes in the investigated parameters were found in patients undergoing chemotherapy, mostly containing fluorouracil, as shown in the following paper. Far from suggesting a widespread use of these methods during chemotherapy administration, we think that some more tools are needed to prevent cardiac toxicity in high-risk patients and some of what we studied may deserve further valuation in chemotherapy clinical trials.